3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
4
Withdrawn
3
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Recurrence
3
Lymphoma, T-Cell, Peripheral
2
Lymphoma, T-Cell
2
Leukemia, Prolymphocytic, T-Cell
2
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma
1
Leukemia, Large Granular Lymphocytic
1
Leukemia
1
Immunoblastic Lymphadenopathy
1
Interventions
Cyclophosphamide
27
fludarabine
18
Rituximab
17
obinutuzumab
11
venetoclax
9
Bendamustine Hydrochloride
9
Lenalidomide
8
zanubrutinib
6
Prednisone
6
Doxorubicin
6
Blood Specimen Collection
6
pembrolizumab
5
fludarabine phosphate
5
Biopsy
5
ibrutinib
4
glofitamab
4
Vincristine
4
Trimethoprim, Sulfamethoxazole Drug Combination
4
Exercise
4
loncastuximab tesirine
3
gamma-Globulins
3
axicabtagene ciloleucel
3
acalabrutinib
3
Temozolomide
3
Surveys and Questionnaires
3
Palliative Care
3
Mycophenolic Acid
3
Methotrexate
3
Mesna
3
Magnetic Resonance Spectroscopy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Lymphoma
×
duvelisib
×
Clear all
NCT06522737
2026-04-06
TERZO
SecuraBio
Phase 3
Recruiting
124 enrolled